Literature DB >> 19937309

[What is proven in the treatment of COPD?].

H Worth1.   

Abstract

The treatment of chronic obstructive pulmonary disease (COPD) with or without emphysema includes prevention, management of exacerbation and of stable disease. Smoking cessation is the most important intervention to reduce the risk of developing COPD and stop its progression. Bronchodilator medications and inhaled glucocorticosteroids are given to reduce symptoms and exacerbations in long-term medical therapy. Pulmonary rehabilitation including exercise training and patient education improves symptoms and morbidity. The management of exacerbations includes intensified treatments with bronchodilators, systemic corticosteroids for 10-14 days, as well as the use of O(2) for patients with hypoxia and non invasive or invasive ventilation in the case of acidosis and hypercapnia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937309     DOI: 10.1007/s00108-009-2459-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

2.  [S3-guideline on ambulant acquired pneumonia and deep airway infections].

Authors:  G Höffken; J Lorenz; W Kern; T Welte; T Bauer; K Dalhoff; E Dietrich; S Ewig; P Gastmeier; B Grabein; E Halle; M Kolditz; R Marre; H Sitter
Journal:  Pneumologie       Date:  2005-09

3.  Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.

Authors:  N Duffy; P Walker; F Diamantea; P M A Calverley; L Davies
Journal:  Thorax       Date:  2005-06-06       Impact factor: 9.139

4.  Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient.

Authors:  J Bott; S Blumenthal; M Buxton; S Ellum; C Falconer; R Garrod; A Harvey; T Hughes; M Lincoln; C Mikelsons; C Potter; J Pryor; L Rimington; F Sinfield; C Thompson; P Vaughn; J White
Journal:  Thorax       Date:  2009-05       Impact factor: 9.139

5.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

6.  Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

Authors:  Richard Casaburi; David Kukafka; Christopher B Cooper; Theodore J Witek; Steven Kesten
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

7.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.

Authors:  Marc Decramer; Bartolome Celli; Steven Kesten; Theodore Lystig; Sunil Mehra; Donald P Tashkin
Journal:  Lancet       Date:  2009-08-27       Impact factor: 79.321

8.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

Authors:  D E O'Donnell; T Flüge; F Gerken; A Hamilton; K Webb; B Aguilaniu; B Make; H Magnussen
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

9.  Bronchodilator responsiveness in patients with COPD.

Authors:  D P Tashkin; B Celli; M Decramer; D Liu; D Burkhart; C Cassino; S Kesten
Journal:  Eur Respir J       Date:  2008-02-06       Impact factor: 16.671

10.  Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial.

Authors:  Heinrich Worth; Christian Schacher; Uwe Dethlefsen
Journal:  Respir Res       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.